Inhibition of nitric oxide synthase induces a selective reduction in tumor blood flow that is reversible with L-arginine.
作者： Vivien E. Prise , David J. Chaplin , Gillian M. Tozer
DOI:
关键词:
摘要: The effect of iv administration of the nitric oxide synthase (NOS) inhibitor N ω-nitro-l-arginine (l-NNA) on tumor blood flow compared with normal tissue blood flow was studied in anesthetized BD9 rats bearing subcutaneous P22 carcinosarcomas. Blood flow was measured by the tissue uptake of radiolabeled iodoantipyrine. The reversibility of blood flow changes was tested by subsequent administration of l-arginine, the natural substrate for NOS. The effect of l-NNA was compared to that of the imidazolineoxyl N-oxide C-PTIO, a …
aacrjournals.org参考文章(32)
N.R. Bastian, C.Y. Yim, J.B. Hibbs, W.E. Samlowski, Induction of iron-derived EPR signals in murine cancers by nitric oxide. Evidence for multiple intracellular targets. Journal of Biological Chemistry. ,vol. 269, pp. 5127- 5131 ,(1994) , 10.1016/S0021-9258(17)37664-0
Hiroshi Maeda, Takaaki Akaike, Masaki Yoshida, Moritaka Suga, Multiple functions of nitric oxide in pathophysiology and microbiology: analysis by a new nitric oxide scavenger. Journal of Leukocyte Biology. ,vol. 56, pp. 588- 592 ,(1994) , 10.1002/JLB.56.5.588
Kenneth D. Aldape, Jay E. Brenman, David S. Bredt, Mark A. Israel, Charles S. Cobbs, Expression of nitric oxide synthase in human central nervous system tumors. Cancer Research. ,vol. 55, pp. 727- 730 ,(1995)
R M Palmer, S Moncada, E A Higgs, NITRIC OXIDE: PHYSIOLOGY, PATHOPHYSIOLOGY, AND PHARMACOLOGY Pharmacological Reviews. ,vol. 43, pp. 109- 142 ,(1991)
Mark W. Dewhirst, David Madwed, Robert E. Meyer, Edgardo T. Ong, Bruce Klitzman, Gary L. Rosner, Richard Dodge, Reduction in tumor blood flow in skin flap tumor after hydralazine is not due to a vascular steal phenomenon Radiation Oncology Investigations. ,vol. 1, pp. 270- 278 ,(1993) , 10.1002/ROI.2970010504
Martin Feelisch, Marc te Poel, Rubén Zamora, Andreas Deussen, Salvador Moncada, Understanding the controversy over the identity of EDRF Nature. ,vol. 368, pp. 62- 65 ,(1994) , 10.1038/368062A0
M. Yoshida, T. Akaike, Y. Wada, K. Sato, K. Ikeda, S. Ueda, H. Maeda, THERAPEUTIC EFFECTS OF IMIDAZOLINEOXYL N-OXIDE AGAINST ENDOTOXIN SHOCK THROUGH ITS DIRECT NITRIC OXIDE-SCAVENGING ACTIVITY Biochemical and Biophysical Research Communications. ,vol. 202, pp. 923- 930 ,(1994) , 10.1006/BBRC.1994.2018
GM Tozer, KM Shaffi, Modification of tumour blood flow using the hypertensive agent, angiotensin II British Journal of Cancer. ,vol. 67, pp. 981- 988 ,(1993) , 10.1038/BJC.1993.180
Silvia P. Andrade, Ian R. Hart, Priscilla J. Piper, Inhibitors of nitric oxide synthase selectively reduce flow in tumour‐associated neovasculature British Journal of Pharmacology. ,vol. 107, pp. 1092- 1095 ,(1992) , 10.1111/J.1476-5381.1992.TB13412.X
Michael R. Horsman, Kent L. Christensen, Jens Overgaard, Relationship between the hydralazine-induced changes in murine tumor blood supply and mouse blood pressure International Journal of Radiation Oncology*Biology*Physics. ,vol. 22, pp. 455- 458 ,(1992) , 10.1016/0360-3016(92)90852-9